[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,056,946
  • Shares Outstanding, K 68,533
  • Annual Sales, $ 189,760 K
  • Annual Income, $ -196,540 K
  • EBIT $ -197 M
  • EBITDA $ -196 M
  • 60-Month Beta 1.91
  • Price/Sales 31.66
  • Price/Cash Flow N/A
  • Price/Book 48.88

Options Overview Details

View History
  • Implied Volatility 49.14% (-25.82%)
  • Historical Volatility 51.85%
  • IV Percentile 23%
  • IV Rank 13.83%
  • IV High 112.19% on 07/08/25
  • IV Low 39.01% on 08/11/25
  • Expected Move (DTE 2) 3.71 (4.14%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 647
  • Volume Avg (30-Day) 163
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 4,706
  • Open Int (30-Day) 3,401
  • Expected Range 85.99 to 93.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.82
  • Number of Estimates 5
  • High Estimate $-0.78
  • Low Estimate $-0.84
  • Prior Year $-0.75
  • Growth Rate Est. (year over year) -9.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
82.89 +8.22%
on 06/02/26
98.37 -8.81%
on 06/15/26
-0.82 (-0.91%)
since 05/15/26
3-Month
74.50 +20.40%
on 03/30/26
100.00 -10.30%
on 03/20/26
+2.32 (+2.66%)
since 03/13/26
52-Week
60.70 +47.78%
on 06/18/25
122.20 -26.60%
on 12/11/25
+26.80 (+42.61%)
since 06/13/25

Most Recent Stories

More News
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years -- - - Bivamelagon therapy achieved progressive reductions...

RYTM : 89.70 (+1.49%)
 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in...

RYTM : 89.70 (+1.49%)
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 89.70 (+1.49%)
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 89.70 (+1.49%)
3 Gold-Medal Mutual Funds to Buy Now

These mutual funds are the crème de la crème of their respective investment categories.

NVDA : 212.45 (+3.54%)
GOOGL : 369.35 (+2.69%)
ONC : 268.20 (+1.41%)
TDVG : 48.81 (+0.46%)
RYTM : 89.70 (+1.49%)
MU : 1,087.99 (+10.84%)
DODIX : 12.80 (+0.16%)
V : 323.82 (+0.44%)
ROST : 236.77 (-1.40%)
PRDGX : 88.44 (+0.43%)
CB : 326.95 (-0.36%)
WMT : 120.82 (-0.18%)
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 89.70 (+1.49%)
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 89.70 (+1.49%)
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France – – Phase 3 analyses...

RYTM : 89.70 (+1.49%)
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 89.70 (+1.49%)
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

-- IMCIVREE ® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026...

RYTM : 89.70 (+1.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

3rd Resistance Point 105.04
2nd Resistance Point 101.71
1st Resistance Point 95.70
Last Price 89.70
1st Support Level 86.36
2nd Support Level 83.03
3rd Support Level 77.02

See More

52-Week High 122.20
Fibonacci 61.8% 98.71
Fibonacci 50% 91.45
Last Price 89.70
Fibonacci 38.2% 84.19
52-Week Low 60.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.